Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax (NVAX) ended the recent trading session at $6.85, demonstrating a -2.28% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.13%. At the same time, ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated coverage of Novavax Inc. (NASDAQ:NVAX) with a Sell rating and a $6 price ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Meanwhile, Novavax also plans to use Warp Speed funds to ramp up COVID-19 vaccine manufacturing. The company has pledged to produce 100 million vaccine doses this year, and the partners could sign ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The news sent company ...

If Novavax can turn the corner on its COVID-19 vaccine production, there will be much brighter days ahead for both investors and the billions globally who desperately need a vaccine.

Novavax says it will be able to deliver 100 million doses per month by the end of September and 150 million doses per month by the end of the year. The Novavax vaccine is what's known as a protein ...